NATR

Business Context and Reporting Period

Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: The Company manufactures and markets nutritional and personal care products (herbal products, vitamins, minerals) sold globally through a direct-selling network of independent Distributors and Managers. Operations are conducted in the U.S. and numerous international markets including South Korea, Mexico, Venezuela, and Japan. A separate division, Synergy Worldwide, focuses on Asian markets.

Key Financial Metrics (Year Ended Dec 31, 2003)

Note: Financial data for 2002 and 2001 has been restated/reclassified to conform to EITF 01-9, which treats volume incentive rebates as a reduction of revenue rather than an operating expense. This reclassification did not affect Net Income or EPS.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 0.5% to $258.2 million in 2003 compared to 2002. This follows a 6.3% decline in 2002. The 2003 decrease was driven by declines in the U.S. market (-3.0%) and international markets (-5.5%), specifically South Korea (increased competition) and Venezuela (political unrest and currency devaluation).
• Profitability Compression: Operating income fell 34% to $7.7 million, and Net Income dropped 28% to $5.1 million. This was primarily due to increased Selling, General, and Administrative (SG&A) expenses (up 40.5% of sales) related to restructuring costs ($2.2 million) and investment in the Synergy Worldwide division.
• Investment Impairments: The Company recorded a $1.8 million impairment loss on its investment in HealtheTech, Inc. in 2003. In 2002, a $3.0 million write-off occurred for investments in Cetalon Corporation.
• Segment Performance: Synergy Worldwide revenue surged 148.8% to $15.1 million due to recruiting efforts in Japan and Thailand, though the segment remained unprofitable with an operating loss of $0.6 million.

Guidance, Outlook, and Risks

• Price Increases: Management implemented a 1% price increase in the U.S. in 2003 and plans a ~2% increase effective April 1, 2004, to offset raw material costs. International price increases are also planned to counter currency devaluations.
• Cost Control: SG&A expenses as a percentage of sales are expected to decrease in 2004 due to cost-cutting measures and restructuring initiated in late 2003.
• Regulatory Risks (Ephedra): The FDA issued a ban on ephedrine alkaloids effective April 12, 2004. Products containing ephedra represent less than 2% of net sales. The Company has replacement products and does not anticipate a material impact on revenue.
• Product Liability: The Company cannot obtain third-party insurance for products containing ephedrine or kava. It utilizes a captive insurance company and accrues liabilities based on actuarial estimates, though there is no assurance these will be sufficient.
• Foreign Exchange: Approximately 45% of sales and 46% of expenses are realized outside the U.S. A strengthening U.S. dollar negatively impacts reported results. The Company does not use derivative instruments for hedging.
• Liquidity: The Company maintains a $15.0 million line of credit, with $5.0 million outstanding at year-end (paid in full by Feb 2004). No long-term debt exists.

Investor Verification Checklist

• Restatement Impact: Verify understanding of the EITF 01-9 reclassification which reduced reported revenue and volume incentive expenses by equal amounts ($39.2 million in 2003) without changing Net Income.
• International Exposure: Assess the specific impact of currency devaluation in Venezuela and political instability on the Latin America segment, which saw revenue drop from $65.4 million (2001) to $51.8 million (2003).
• SG&A Efficiency: Monitor if the 2004 SG&A expense ratio improves as management projects, given the 40.5% ratio in 2003 was driven by restructuring and Synergy expansion.
• Stock Repurchases: Note that the Company spent $11.8 million repurchasing 1.3 million shares in 2003 and has no current Board authorization for further open-market purchases.
• Product Liability Reserves: Review the adequacy of self-insurance accruals for product liability, particularly regarding the inability to insure ephedra/kava products.